Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 1996;8(3):205–212. doi: 10.1007/BF01877206

Oral application of cytokines

Jerzy A Georgiades 1, W Robert Fleischmann Jr 2,✉
PMCID: PMC7088415  PMID: 8813332

Summary

A number of different laboratories reported on studies with orally administered interferons and cytokines. Their observations extend previous observations which showed that orally administered interferons and cytokines can exert both local and systemic effects. As difficult as it may be to understand how orally administered interferons and cytokines may exert both effects, the increasing number of laboratories that demonstrate biological effects with orally administered cytokines suggests that serious consideration be given to the possibility that orally administered interferons and cytokines can indeed exert effects. They also raise the possibility that these effects may have biological relevance for the treatment of human disease. Moreover, they may indicate that the nasal/oral region is a window on the environment. It is most important, however, to assure that these experiments are performed with special care to avoid presenting preliminary data that is not properly controlled. It is essential to carry out these studies with sufficient animals or patients to ascertain their significance; and to plan the studies as double-blind evaluations to avoid misinterpretations when subjective tests are used. Nevertheless, the overall data presented give one the impression of an area that should be pursued.

Keywords: Public Health, Interferon, Biological Effect, Human Disease, Preliminary Data

References

  1. Babiuch L, Mian M, Kaminska E, Szymanska B, Georgiades JA. An interim report on the effect of natural human interferon alpha (IFNα) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1) Arch Immunol Ther Expl. 1993;41:213–219. [PubMed] [Google Scholar]
  2. Babiuch L, Mian M. Oral mucosal administration of natural human alpha-interferon in HIV-1 seropositive patients. J. Interferon Res. 1994;14:S140. [Google Scholar]
  3. Baqar S, Pacheco ND, Rollwagen FM. Modulation of mucosal immunity againstCampylobacter jejuni by orally administered cytokines. Antimicr Agents Chemother. 1993;37:2688–92. doi: 10.1128/aac.37.12.2688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baqar S, Rollwagen F, Pacheco N, Frazier L, Bourgeois A. Modulation of mucosal immunity againstCampylobacter jejuni by orally administered cytokines. Workshop presentation, 1994. [DOI] [PMC free article] [PubMed]
  5. Blalock JE, Baron S. Interferon-induced transfer of viral resistance between animal cells. Nature. 1977;269:922–25. doi: 10.1038/269422a0. [DOI] [PubMed] [Google Scholar]
  6. Cummins JM, Gawthrop J, Hutcheson DP, Cummins MJ, Zeck D. The effect of low dose oral human interferon alpha therapy on diarrhea in veal calves. Archr Immunol Ther Expl. 1993;41:199–203. [PubMed] [Google Scholar]
  7. Cummins JM, Hutcheson DP, Cummins MJ, Georgiades JA, Richards AB. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotrachetis virus. Arch Immunol Ther Expl. 1993;41:193–97. [PubMed] [Google Scholar]
  8. Cummins JM, Hutcheson DP. Effect of interferon on feedlot cattle. Proc American Assoc Bovine Pract. 1983;15:109–15. [Google Scholar]
  9. Cummins JM, Hutcheson DP. Low dosage of interferon to enhance vaccine efficiency in feedlot calves. Proc American Assoc Bovine Pract. 1986;18:135–38. [Google Scholar]
  10. Cummins JM, Rosenquist BD. Protection of calves against rhinovirus infection by nasal secretion interferon induced by infectious bovine rhinotracheitis virus. Am J Vet Res. 1980;41:161–65. [PubMed] [Google Scholar]
  11. Cummins JM, Tompkins MB, Olsen RG, Tompkins WA, Lewis MG. Oral use of human alpha interferon in cats. J Biol Response Mod. 1988;7:513–23. [PubMed] [Google Scholar]
  12. Degre M. Interferons and other cytokines in infectious diseases: molecular mechanisms and clinical value. Review speech, 1994 ISICR Annual Meeting.
  13. Fleischmann WR, Jr, Fields EE, Wang JL, Hughes TK, Stanton GJ. Modulation of peripheral leukocyte counts in mice by oral administration of interferons. Proc Soc Exp Biol Med. 1991;197:424–30. doi: 10.3181/00379727-197-43277. [DOI] [PubMed] [Google Scholar]
  14. Fleischmann WR, Jr, Koren S, Fleischmann CM. Orally administered interferons exert their WBC suppressive effects via a novel mechanism. Proc Soc Exp Biol Med. 1992;201:200–207. doi: 10.3181/00379727-201-43499. [DOI] [PubMed] [Google Scholar]
  15. Georgiades JA, Babiuch L. Results of the prolonged use of natural human interferon alpha (nHuIFNα) lozenges in the treatment of human immune deficiency virus infection. Cytokine. 1994;6:572. [Google Scholar]
  16. Georgiades JA, Caban J, Zyrkowska-Bieda T, Zejc M, Janas-Skulina U, Ciesla A. Natural human interferon alpha (nHuIFNα) given orally has different effects on patients with distinct forms of chronic viral hepatitis B (CHBV). In: McNeil, J ed. Interferons and interacting cytokines: cellular and clinical response and resistance. Serono Symposia USA, 1994: 48.
  17. Georgiades JA, Krusel ML, Serman G. Transfer of antiviral resistance by spleen and blood cells of mice receiving low oral doses of IFN alpha or gamma. J Interferon Res. 1988;9:213. [Google Scholar]
  18. Greenberg SB, Harmon MW, Johnson PE, Couch RB. Antiviral activity of intranasally applied human leukocyte interferon. Antimicrob Agents Chemother. 1978;14:596–600. doi: 10.1128/aac.14.4.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM. Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon. N Engl J Med. 1986;314:71–5. doi: 10.1056/NEJM198601093140202. [DOI] [PubMed] [Google Scholar]
  20. Higgins PG, Phillpots RJ, Scott GM, Wallace J, Bernhardt LL, Tyrell DAJ. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother. 1983;24:713–15. doi: 10.1128/aac.24.5.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hulton MR, Levin DL, Freedman LS. Randomized, placebo-controlled double-blind study of low-dose oral interferon-α in HIV-1 antibody positive patients. J AIDS. 1992;5:1084–90. [PubMed] [Google Scholar]
  22. Hutchinson V, Cummins JM. Low-dose oral interferon in patient with AIDS. Lancet. 1987;2:1530–31. doi: 10.1016/s0140-6736(87)92671-7. [DOI] [PubMed] [Google Scholar]
  23. Jordan WC. Three open-label studies of oral interferon alpha in the treatment of HIV disease. Natl Med Assoc. 1994;86:57–62. [PMC free article] [PubMed] [Google Scholar]
  24. Kaiser G, Jaeger H, Birkmann J, Poppinper J, Cummins JM, Gallmeier WM. Low-dose oral natural human interferon-α in 29 patients with HIV-1 infections: A double-blind randomized, placebo-controlled trial. AIDS. 1992;6:563–69. doi: 10.1097/00002030-199206000-00007. [DOI] [PubMed] [Google Scholar]
  25. Koech DK, Obel AO, Minowada J, Hutchinson VA, Cummins JM. Low dose oral alpha-interferon therapy for patients seropositive for the human immunodeficiency virus type-1 (HIV-1) Mol Biother. 1990;2:91–5. [PubMed] [Google Scholar]
  26. Koren S, Fleischmann WR., Jr Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2. J Interferon Res. 1994;14:343–46. doi: 10.1089/jir.1994.14.343. [DOI] [PubMed] [Google Scholar]
  27. Koren S, Fleischmann WR., Jr Orally, administered interferons suppress bone marrow function. Proc Soc Exp Biol Med. 1993;204:155–64. doi: 10.3181/00379727-204-43646. [DOI] [PubMed] [Google Scholar]
  28. Merigan TC, Hall TS, Reed SE, Tyrell DAJ. Inhibition of respiratory virus infection by locally applied interferon. Lancet 1973; 563–67. [DOI] [PubMed]
  29. Moore BR, Krakowka S, Cummins JM, Robertson JT. Oral administration of interferon-alpha for treatment of inflammatory airway disease in standard-bred racehorses. J Interferon Res. 1994;14:S142. [Google Scholar]
  30. Mukunyandela M, Richards AB, Cummins MJ. Treatment of symptomatic HIV-1 infected patients with low dose oral natural human interferon alpha. J Interferon Res. 1994;14:S191. [Google Scholar]
  31. Ohashi K, Akazawa R, Kurimoto M. Effects of interferon-α on a reduced release of interleukin-8 from latently HIV-1 infected monocytic cell line U937 cells. J Interferon Res. 1994;14:129–32. doi: 10.1089/jir.1994.14.129. [DOI] [PubMed] [Google Scholar]
  32. Ohashi K, Takeuchi M, Fujioka N, Akazawa R, Sakamoto K, Kurimoto M, Minowada J. Interferon alpha (IFNα) in antimicrobial mechanisms in the oral cavity: Possibility of oral-mucosal use of IFNα to treat fungal infections in the oral cavity. Workshop presentation, 1994.
  33. Schafer TW, Lieberman M, Cohen M, Came PE. Interferon administered orally: Protection of neonatal mice from lethal virus challenge. Science. 1972;176:1326–27. doi: 10.1126/science.176.4041.1326. [DOI] [PubMed] [Google Scholar]
  34. Smith AL, Barthold SW, Beck DS. Intranasally administered alpha/beta interferon prevents extension of mouse hepatitis virus strain JHM into the brains of BALB/cByJ mice. Antiviral Res. 1987;8:239–46. doi: 10.1016/S0166-3542(87)80002-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Smith J, Chi D, Krishnawamy G, Berk S. Effect of IFNα on HLA-DR expression in human buccal epithelial cells. Workshop presentation, 1994. [PubMed]
  36. Sperber SJ, Gocke DJ, Haberzettl CA, Pestka S. Low-dose oral recombinant interferon-alpha A in patients with HIV-1 infection: A blinded pilot study. AIDS. 1993;7:693–97. [PubMed] [Google Scholar]
  37. Tonkonogy S, Tompkins, M, Tompkins W. Effect of intranasal administration of interferon-alpha on lymphoid cell phenotype and function. Workshop presentation, 1994.
  38. Toth T, Cummins J, Moore D. Effects of very-low-dose oral cytokine treatment on hematological values in feline leukemia positive cells. J Interferon Res. 1994;14:S187. [Google Scholar]
  39. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J Infect Dis. 1986;154:443–47. doi: 10.1093/infdis/154.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Witt PL, Goldstein D, Storer BE, Grossberg SE, Flashner M, Colby CB, Borden EC. Absence of biological effect of orally administered interferon-ßser. J Interferon Res. 1992;12:411–13. doi: 10.1089/jir.1992.12.411. [DOI] [PubMed] [Google Scholar]
  41. Yamamoto JR, Kruzel ML, Louie H, Georgiades JA. Inhibition of human immunodeficiency virus type 1 replication by human interferons alpha, beta, and gamma. Arch Immunol Ther Expl. 1993;41:185–91. [PubMed] [Google Scholar]
  42. Young AS, Maritim AC, Kariuki DP, Stagg DA, Wafula JM, Mutugi JJ, Cummins JM, Richards AB, Burns C. Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. Parasitol. 1990;101:201–209. doi: 10.1017/s0031182000063241. [DOI] [PubMed] [Google Scholar]
  43. Zielinska W, Paszkiewicz J, Korczak A, Wlasiuk M, Zóltowska A, Szutowicz A, Cummins JM, Georgiades JA. Treatment of fourteen chronic active HBsAg+, HBeAg+ hepatitis patients with low dose natural human interferon alpha administered orally. Arch Immunol Ther Expl. 1993;41:241–51. [PubMed] [Google Scholar]
  44. Zielinska W, Paszkiewicz J, Korczak A, Wlasiuk M, Zóltowska A, Szutowicz A, Cummins JM, Georgiades JA. Treatment of six patients with chronic active HCV hepatitis with low dose natural human interferon alpha administered orally. Arch Immunol Ther Expl. 1993;41:253–57. [PubMed] [Google Scholar]
  45. Zielinska W, Paszkiewicz J, Korczak-Rogon A, Wlasiuk M, Cummins JM, Georgiades JA. Long-term follow-up of 30 chronic active hepatitis B patients treated with low dose natural human interferon alpha administered orally. J Interferon Res. 1994;14:146. [Google Scholar]

Articles from Biotherapy (Dordrecht, Netherlands) are provided here courtesy of Nature Publishing Group

RESOURCES